PanTher Therapeutics launches second trial for chemotherapy patch
US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer therapy more tolerable. The Phase …
US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer therapy more tolerable. The Phase …
Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, aimed at …
Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview …
PYC Therapeutics is set to begin Part B in its single ascending dose (SAD) study of the drug candidate, PYC-003, …
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have authorised AB Science’s confirmatory Phase III …
A court has ordered several US government agencies, including the US Food and Drug Administration (FDA), to restore healthcare resources …
Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) patients for 5.5 years and …
Headlands Research has acquired Puerto Rico’s clinical research site, CMRCenter (CMRC), for an undisclosed sum. This strategic move broadens Headlands' reach …
Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or …
The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted approval to the investigational new drug …
BioAtla has presented first-in-human Phase I study data of its anti-cancer therapy, BA3182, targeting those with treatment-refractory metastatic adenocarcinoma. The findings …
A study conducted by investigators across Europe has found that the UK had shorter clinical trial approval and set-up times …
Opioid use disorder (OUD) has become a mounting public health crisis in the US, often disproportionately affecting individuals in the …
Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant …
The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community …